{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'MONITORING:', 'Obtain complete blood count with', 'For bilirubin or INR criteria:', 'differential to assess eosinophilia', 'Repeat liver chemistries (include ALT, AST,', 'Record the appearance or worsening of', 'alkaline phosphatase, bilirubin) and perform', 'clinical symptoms of liver injury, or', 'liver event follow up assessments within 24', 'hypersensitivity, on the AE report form', 'hours', 'Record use of concomitant medications on', 'Monitor participants twice weekly until liver', 'the concomitant medications report form', 'chemistries resolve, stabilize or return to', 'including acetaminophen, herbal', 'within baseline', 'remedies, other over the counter', 'medications.', 'A specialist or hepatology consultation is', 'recommended', 'Record alcohol use on the liver event', 'alcohol intake case report form', 'For All other criteria:', 'Repeat liver chemistries (include ALT, AST,', 'For bilirubin or INR criteria:', 'alkaline phosphatase, bilirubin) and perform', 'liver event follow up assessments within 24-', 'Anti-nuclear antibody, anti-smooth muscle', '72 hours', 'antibody, Type 1 anti-liver kidney', 'microsomal antibodies, and quantitative', 'Monitor participants weekly until liver', 'total immunoglobulin G (lgG or gamma', 'chemistries resolve, stabilize or return to', 'globulins).', 'within baseline', 'Serum acetaminophen adduct HPLC', 'assay (quantifies potential acetaminophen', 'contribution to liver injury in participants', 'with definite or likely acetaminophen use in', 'the preceding week [James, 2009]).', 'Liver imaging (ultrasound, magnetic', 'resonance, or computerised tomography)', 'and /or liver biopsy to evaluate liver', 'disease; complete Liver Imaging and/or', 'Liver Biopsy eCRF forms.', '1.', 'Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue randomized treatment for that participant if ALT 3xULN and bilirubin', '2xULN.', '2.', 'All events of ALT 3xULN and bilirubin > 2xULN (>35% direct bilirubin) or ALT > 3xULN and INR>1.5, if INR', \"measured which may indicate severe liver injury (possible 'Hy's Law'), must be reported as an SAE (excluding\", 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to participants receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '4.', 'Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C', 'RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain', 'heterophile antibody or monospot testing); Hepatitis E IgM antibody', '5.', 'If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus', '(where needed) Le Gal, 2005].', '6.', 'Record the date/time of the PK blood sample draw and the date/time of the last dose of randomized treatment', \"prior to blood sample draw on the eCRF. If the date or time of the last dose is unclear, provide the participant's\", '96']['2016N298481_0', 'CONFIDENTIAL', '205270', 'best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected', 'in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shipping are', 'in the SRM.', 'Phase 3-4 liver chemistry increased monitoring criteria with continued therapy', 'Liver Chemistry Increased Monitoring Criteria - Liver Monitoring Event', 'Criteria', 'Actions', 'ALT >5xULN and <8xULN and bilirubin', 'Notify GSK within 24 hours of learning of the', '<2xULN without symptoms believed to', 'abnormality to discuss participant safety.', 'be related to liver injury or', 'Participant can continue randomized treatment', 'hypersensitivity, and who can be', 'monitored weekly for 2 weeks.', 'Participant must return weekly for repeat liver', 'OR', 'chemistries (ALT, AST, alkaline phosphatase,', 'bilirubin) until they resolve, stabilise or return to', 'ALT >3xULN and <5xULN and bilirubin', 'within baseline', '<2xULN without symptoms believed to', 'be related to liver injury or', 'If at any time participant meets the liver chemistry', 'hypersensitivity, and who can be', 'stopping criteria, proceed as described above', 'monitored weekly for 4 weeks.', 'If ALT decreases from ALT >5xULN and <8xULN to', '>3xULN but <5xULN, continue to monitor liver', 'chemistries weekly.', 'If, after 4 weeks of monitoring, ALT <3xULN and', 'bilirubin <2xULN, monitor participants twice monthly', 'until liver chemistries normalize or return to within', 'baseline.', 'References', 'James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee', 'WM. Pharmacokinetics of acetaminophen-adduct in adults with acetaminophen overdose', 'and acute Liver failure. Drug Metab Dispos 2009; 37:1779-1784.', 'Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, D\u00e9ny P, Gault E. Quantification', 'of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different', 'patterns of virological response to interferon therapy in chronically infected patients J', 'Clin Microbiol. 2005;43(5):2363-2369.', '97']\n\n###\n\n", "completion": "END"}